Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | TK2 | O00142 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL3437224 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL778861 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL10382149 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL14596596 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL13497202 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12718344 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL767986 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12296879 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 33067 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146286-A1 | SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS | GATEHOUSE BIO INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094697-A | Aptamer conjugates for targeted degradation of osteopetron | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081333-A | Theophylline aptamer and virtual screening method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122071706-A | Agents and methods for silencing HIF2A | 杭州迪纳元昇生物科技有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260139255-A1 | RNAi Agent Targeting PCSK9 and Use Thereof | SYNERK BIOTECH LTD (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026103905-A1 | DSRNA MOLECULE FOR REGULATING ALK7 EXPRESSION | 大睿生物医药科技(上海)有限公司 | 2026-05-21 | — | — | WO | claimed |
| EP-4745237-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF | YUN HO BIO CO., LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4745238-A1 | OLIGONUCLEOTIDE TARGETING ANGIOTENSINOGEN AND USE THEREOF | Anlong Biopharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122060746-A | Nucleic acid aptamer targeting iron regulatory protein IRPs and application thereof | 西北农林科技大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-1989010129-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES FOR WOUND HEALING | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | WO | claimed |
| WO-1989009778-A1 | OLIGONUCLEOTIDE CONTAINING 6-THIOGUANINE AT A PREDETERMINED SITE | CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY (US) | 1989-10-19 | — | — | WO | claimed |
| CN-1034134-A | Be used for the treatment of compositions and preparation method that back virus merges cancer | UNIV LIVERPOOL (GB) | 1989-07-26 | — | — | CN | claimed |
| WO-1989003838-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0306597-A2 | Antiviral nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-15 | — | — | EP | claimed |
| US-4786724-A | INTERMEDIATES FOR SOLID PHASE SYNTHESIS | NORTHWESTERN UNIVERSITY (US) | 1988-11-22 | — | — | US | claimed |
| CN-87105612-A | PYRIMIDINE DERIVATIVES | — | 1988-03-16 | — | — | CN | claimed |
| CN-87105758-A | Pyrimidine derivatives, their production and use | — | 1988-03-02 | — | — | CN | claimed |
| EP-0243153-A2 | Human G-CSF protein expression | IMMUNEX CORPORATION (US) | 1987-10-28 | — | — | EP | claimed |
| EP-0113452-A2 | Magnetic particles as supports for organic synthesis | GENETICS INSTITUTE, INC. (US) | 1984-07-18 | — | — | EP | claimed |